Adamis Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Adamis Pharmaceuticals is a neuro-biotechnology company in the early stages of clinical development. Its primary objective is to create and sell highly successful treatments for a range of neurological disorders that currently lack effective medical solutions. These treatments cover diverse areas like allergies, opioid overdose, as well as respiratory and inflammatory diseases.
Adamis Pharmaceuticals has raised $8.0M across 1 funding round on record, the most recent an undisclosed round of $8.0M announced in Aug 2023.
That round is in line with the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Adamis Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Aug 2023.
Adamis Pharmaceuticals Funding Rounds
Adamis Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Adamis Pharmaceuticals Funding Compared to Other Biotechnology Startups
Adamis Pharmaceuticals' latest round of $8.0M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Adamis Pharmaceuticals in Biotechnology and San Diego
Companies Similar to Adamis Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Adamis Pharmaceuticals Funding FAQs
What does Adamis Pharmaceuticals do?
Adamis Pharmaceuticals is a neuro-biotechnology company in the early stages of clinical development. Its primary objective is to create and sell highly successful treatments for a range of neurological disorders that currently lack effective medical solutions. These treatments cover diverse areas like allergies, opioid overdose, as well as respiratory and inflammatory diseases.
How much funding has Adamis Pharmaceuticals raised?
Adamis Pharmaceuticals has raised $8.0M across 1 round on record. The most recent is an undisclosed round of $8.0M announced in Aug 2023.
When did Adamis Pharmaceuticals last raise funding?
Adamis Pharmaceuticals' most recent funding round on record is an undisclosed round of $8.0M, announced in Aug 2023.
Who is the CEO of Adamis Pharmaceuticals?
Dennis J Carlo is listed as CEO at Adamis Pharmaceuticals.
Where is Adamis Pharmaceuticals headquartered?
Adamis Pharmaceuticals is based in San Diego, California, United States.
How many employees does Adamis Pharmaceuticals have?
Adamis Pharmaceuticals is in the 11-50 employee band.
How does Adamis Pharmaceuticals' funding compare to other Biotechnology startups?
Adamis Pharmaceuticals' latest round of $8.0M is in line with the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Adamis Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Adamis Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.